Incyte, Eli Lilly: Baricitinib Meets Main Endpoint in Alopecia Areata Study
By Colin Kellaher
Eli Lilly & Co. and Incyte Corp. on Wednesday said a Phase 3
study evaluating the efficacy and safety of baricitinib met the key
goal in the treatment of the autoimmune disorder alopecia
The companies said both the two-milligram and four-milligram
once-daily doses in adults with severe alopecia areata met the
primary efficacy endpoint at week 36, showing a statistically
significant improvement in scalp hair regrowth compared to those on
There are currently no FDA-approved treatments for alopecia
areata, which can cause unpredictable hair loss on the scalp, face
and other areas of the body.
Eli Lilly and Incyte said the study marks the first Phase 3
trial with positive results in patients with the disorder, adding
that they expect data from an additional Phase 3 study in the first
half of the year.
Indianapolis-based Eli Lilly signed an exclusive worldwide
license and collaboration agreement with Incyte, a Wilmington,
Del., biopharmaceutical company, in late 2009 to develop and
commercialize baricitinib and other compounds for inflammatory and
The companies last March received breakthrough-therapy
designation from the U.S. Food and Drug Administration for
baricitinib for the treatment of alopecia areata.
Write to Colin Kellaher at email@example.com
(END) Dow Jones Newswires
March 03, 2021 07:13 ET (12:13 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.